<DOC>
	<DOCNO>NCT02496910</DOCNO>
	<brief_summary>This Randomized , open-label , single-dose , 2-treatment , 2-period , 2-sequence crossover design .</brief_summary>
	<brief_title>PK Study YH22162 FDC Compared Combination Twynsta Hygroton</brief_title>
	<detailed_description>This 2 2 cross-over study evaluate pharmacokinetics YH22162 FDC compare reference twynsta Hygroton co-administered two group enrol healthy adult male subject fast condition . Subjects admit clinic evening Day 1 . All subject receive single oral dose YH22162 FDC twynsta Hygroton co-administered morning Day 1 . All subject remain clinical unit completion assessment Day 2 include collection post-dose PK sample . Subjects return clinic pharmacokinetic sample schedule time . The two treatment period separate washout period .</detailed_description>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Chlorthalidone</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Healthy male female body mass index ( BMI ) 18.5 25 kg/m2 2. Who suffer clinically significant disease 3 . Provision sign write informed consent 1 . History clinically significant disease 2 . A history drug abuse presence positive reaction drug abuse potential urine screening drug . 3 . Administration investigational product within 3 month prior first dose . 4 . Volunteers consider eligible clinical trial investigator ( study doctor ) due reason include laboratory test result , ECGs , vital sign . 5 . Sitting blood pressure meeting follow criterion screen : 150 ≥ systolic blood pressure ≤100 ( mmHg ) 100 ≥ diastolic blood pressure ≤ 60 ( mmHg )</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>